The Atriva Scientific Board
![](https://atriva-therapeutics.com/wp-content/uploads/2021/08/oliver-planz.jpg)
Prof. Oliver Planz, Ph.D.,
Chair of Scientific Board
Co-inventor of the technology, expert in antiviral research and translational preclinical R&D up to clinical studies. Advises the WHO on antiviral strategies against influenza. More than 150 publications and over 40 patents
![](https://atriva-therapeutics.com/wp-content/uploads/2021/08/stephan_ludwig.jpg)
Prof. Stephan Ludwig, Ph.D., Board Member, Universität Münster (D)
Head of Institute of Molecular Virology at Westfälische Wilhelms-Universität Münster, Germany. Co-inventor of the technology, globally renowned expert in influenza virus-cell interactions. Over 250 scientific publications and more than 15 patents.
![](https://atriva-therapeutics.com/wp-content/uploads/2021/08/stephan_pleschka.jpg)
Prof. Stephan Pleschka, Ph.D.
Universität Gießen (D), Co-inventor of the technology. Expert in replication, infection and cell-virus interactions of the influenza virus. Advisor to biotech companies.
![](https://atriva-therapeutics.com/wp-content/uploads/2021/08/frans_van_dalen.jpg)
Frans van Dalen,
Director of Meneldor B.V.
Project Management, QA/QP, R&D and Regulatory Affairs experience of more than 25 years regarding global development of generics, biosimilars and New Biological Entities (NBE). More than 25 patents. Co-founder of Synthon Inc.